Image may be NSFW.
Clik here to view.
Braeburn Pharmaceuticals and Knight Therapeutics (TSE:GUD) said today that Health Canada has agreed to review Knight’s new drug submission for Probuphine, a buprenorphine subdermal implant designed to treat opioid drug dependence.
In February last year, Braeburn and Knight inked an exclusive distribution and sublicense deal, giving Knight the exclusive right to distribute Probuphine in Canada.
Get the full story at our sister site, Drug Delivery Business News.
The post Braeburn, Knight seek Health Canada nod for opioid dependence implant appeared first on MassDevice.
